Gateway Investment Advisers LLC trimmed its holdings in shares of PerkinElmer, Inc. (NYSE:PKI) by 8.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,154 shares of the medical research company’s stock after selling 363 shares during the quarter. Gateway Investment Advisers LLC’s holdings in PerkinElmer were worth $400,000 as of its most recent SEC filing.
Several other hedge funds have also made changes to their positions in PKI. Quadrant Capital Group LLC acquired a new position in shares of PerkinElmer during the 1st quarter worth approximately $25,000. Financial Gravity Wealth Inc. acquired a new position in shares of PerkinElmer during the 1st quarter worth approximately $52,000. Signaturefd LLC raised its stake in shares of PerkinElmer by 171.5% during the 1st quarter. Signaturefd LLC now owns 809 shares of the medical research company’s stock worth $78,000 after buying an additional 511 shares during the period. Hilton Capital Management LLC acquired a new position in shares of PerkinElmer during the 1st quarter worth approximately $82,000. Finally, South Dakota Investment Council acquired a new position in shares of PerkinElmer during the 1st quarter worth approximately $87,000. 95.51% of the stock is owned by institutional investors and hedge funds.
Several research firms recently commented on PKI. Raymond James increased their price objective on S&P Global from $226.00 to $246.00 and gave the company an “outperform” rating in a research note on Wednesday, July 10th. Goldman Sachs Group downgraded TerraForm Power from a “neutral” rating to a “sell” rating and set a $12.00 price objective for the company. in a research note on Tuesday, April 9th. They noted that the move was a valuation call. Wood & Company reissued an “average” rating and issued a $49.00 price objective on shares of PerkinElmer in a research note on Friday. Wolfe Research began coverage on Waters in a research note on Thursday, May 30th. They issued an “underperform” rating for the company. Finally, Zacks Investment Research raised Icon from a “hold” rating to a “buy” rating and set a $157.00 price objective for the company in a research note on Thursday, May 30th. Eleven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $79.17.
PerkinElmer (NYSE:PKI) last issued its earnings results on Thursday, April 25th. The medical research company reported $0.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.03. PerkinElmer had a return on equity of 15.98% and a net margin of 8.89%. The business had revenue of $648.70 million during the quarter, compared to the consensus estimate of $645.38 million. During the same period last year, the company earned $0.63 EPS. The company’s revenue for the quarter was up .7% on a year-over-year basis. On average, sell-side analysts predict that PerkinElmer, Inc. will post 4.05 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, August 9th. Shareholders of record on Friday, July 19th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date of this dividend is Thursday, July 18th. PerkinElmer’s dividend payout ratio (DPR) is presently 7.76%.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Further Reading: Why is the ROA ratio important?
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.